Inceptua Medicines Access and Onconova Therapeutics Announce Pre-approval Access Collaboration for Rigosertib in Selected Countries Outside the US
06 déc. 2019 07h30 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa. and LUXEMBOURG, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel...
Onconova Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering
25 nov. 2019 09h26 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat...
Onconova Therapeutics, Inc. Announces $11.0 Million Public Offering
21 nov. 2019 11h23 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat...
Onconova Therapeutics Announces Exclusive License Agreement with Knight Therapeutics for Rigosertib in Canada
21 nov. 2019 10h16 HE
|
Onconova Therapeutics, Inc.
Knight receives exclusive license to commercialize rigosertib in CanadaOnconova eligible to receive up to CAD 33.95 million in clinical, regulatory, and sales-based milestones and tiered double-digit...
Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Exposition
07 nov. 2019 07h30 HE
|
Onconova Therapeutics, Inc.
Oral presentation will feature efficacy and safety data from Expanded Phase 2 Trial of oral rigosertib in combination with azacitidine Four poster presentations to feature: biomarker...
Onconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development Update
24 oct. 2019 07h30 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. Announces $3.4 Million Registered Direct Offering of Common Stock
23 sept. 2019 08h52 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit
16 sept. 2019 07h30 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova Therapeutics, Inc. Reports Business Highlights and Second Quarter 2019 Financial Results
14 août 2019 07h30 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Onconova Therapeutics and Mission Bio Partner to Advance Precision Oncology Clinical Trials Employing Single-Cell Genomics
12 août 2019 07h30 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa. and SOUTH SAN FRANCISCO, Calif., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel...